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A B S T R A C T
Introduction. Sexual dysfunction is signiﬁcantly more prevalent in women than in men. However, to date, no
satisfactory oral treatment is yet available.
Aim. The aim of this study was to study the effects of adenosine monophosphate (AMP) alone or its combination
with L-Arginine on the relaxation of the female rabbit corpus cavernosum.
Methods. Cylinder strips from the corporal body of the excised clitoris from female New Zealand White rabbits were
incubated in Krebs solution. Phenylephrine (PE) precontraction was achieved, then the drugs AMP and L-Arginine
were administered either independently or in sequential combinations to the strips under precontracted conditions.
Main Outcome Measures. Contraction percentages were compared.
Results. When precontraction was induced by PE 8 μM or 20 μM, AMP was shown to induce relaxation up to 25%
in a dose-dependent manner. The relaxation induced by L-Arginine reached 15.6% at 5.10−4 M vs. 16.5% at AMP
5.10−4 M under the same experimental conditions. Nitric oxide (NO) synthase inhibitor N-nitro-L-arginine strongly
inhibited the relaxing effect provoked by AMP, suggesting that the action mechanism of this nucleotide is related to
the NO pathway. The combination of L-Arginine at 5.10−4 M with AMP at different doses ranging from 5.10−4 M to
10−3 M signiﬁcantly ampliﬁed the relaxing response up to 40.7% and 58%, respectively.
Conclusions. Our results demonstrate that AMP induces a relaxing effect on the female rabbit corpora. They also
show that L-Arginine and AMP can potentiate each other and that a synergistic effect can be obtained by their
combined use. Because only slight differences exist between both sexes in response to NO donors and/or nucleotide
purines or in their use together, it is very likely that close biochemical mechanisms, although not to the same degree
and not quite similar, are involved in the engorgement of the penis and the clitoris of New Zealand White rabbits.
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Introduction
Over the past two decades, greater attentionhas been paid to male impotence than sexual
disorders in women. Scientiﬁc investigation has
primarily focused on male sexual dysfunction. In
comparison, however, there has been a dearth of
research concerning the physiology and the
functional mechanisms underlying female sexual
dysfunction (FSD). In many respects, the epide-
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miological study published in 1999 by the National
Health and Social Survey [1] was the ﬁrst major
study to address this problem. It conﬁrmed that
women not only suffer from sexual dysfunction, but
it also revealed that the prevalence of this disorder
is even more signiﬁcant in women than in men
(43% vs. 31%, respectively). Since then, FSD has
been identiﬁed as being ofwidespread public health
concern driven by many possible underlying causes
responsible for desire, arousal, orgasm, or pain
disorders and in some cases, a combination of these
conditions. It is now accepted that these disorders
deserve a speciﬁc therapeutic approach that should
not be limited to psychosocial and relationship
aspects alone but sometimes extended to the use of
speciﬁc drugs as in the case of female sexual arousal
disorders (FSAD) and hypoactive sexual desire.
This has given rise to several scientiﬁc projects to
assess the problem of FSD. However, to date, no
reported study, to our knowledge, has emerged as a
satisfactory therapeutic solution. Further studies
are required to broaden our knowledge in the ﬁeld
of FSD.Therefore, wewere prompted to conduct a
study based on a program dedicated to the search of
vasoactive drugs, which would exclusively focus on
the treatment of FSAD.
In a previously reported study, we evaluated the
effect of adenosine monophosphate (AMP) com-
bined with L-Arginine on the mechanism of erec-
tion in the male rabbit penis [2]. We were able to
show a synergistic effect because of these combi-
nations on strips of smooth muscle corpus
cavernosum (CC). The present study was designed
to evaluate the effect of the same compounds
alone, or in combination, on the female New
Zealand rabbit clitoral CC. The existence of close
similarities between the rabbit and the male
human erectile tissues, which are greater than that
between men and other mammal erectile speci-
mens, has been widely documented [3–6]. Mor-
phological and physiological similarities between
male and female New Zealand rabbit CC have also
been described [7,8]. Therefore, the female New
Zealand White rabbit was selected, for this pre-
liminary approach, as it was considered the most
suitable animal model.
Materials and Methods
Strip Preparation
Healthy female New Zealand White rabbits
weighing 2–2.4 kg and 10–12 weeks of age were
sacriﬁced by an overdose of sodium pentobarbital
injected into the marginal vein of the ear. The
clitoris was excised from surrounding external
genitalia and placed in Krebs solution equilibrated
with 95% O2 and 5% CO2 at 4°C. The corporal
body was dissected free from the tunica and then
sliced into four cylinder strips (two proximal, two
distal) of approximately 4–5 mm each as previously
described by other authors [9].
Tissue Bath Setup
Longitudinal strips were attached to force trans-
ducers using silk sutures. They were incubated in
Krebs solution in 25 mL organ baths, equilibrated
with 95% O2 and 5% CO2 and maintained at
37.5°C. Isometric strip tension was recorded
through an acquisition unit (MP30, BioPac,
Goleta, CA, USA) connected to a computer data-
base. After mounting, each strip was allowed to
equilibrate with a basal tension between 0.20 g and
0.25 g for at least 2 to 3 hours. During this time, the
harvested segments were washed regularly.
Drug Administration
Phenylephrine (PE) (Sigma, Saint-Louis, MO,
USA) precontraction was achieved by the addition
of 8 or 20 μM (as indicated by the manufacturer) to
each bath in order to reach a stable strip contracting
effect. Although 8 μMPEwas generally considered
sufﬁcient with no detectable change at 20 μM PE,
we preferred to use the 20 μM dosage in order to
obtain the highest possible precontraction effect.
Drugs AMP (Interchemica S.r.l., Strambino, Italy)
and L-Arginine (Sigma-Aldrich, Saint-Quentin-
Fallavier, France) were administered either inde-
pendently or in sequential combinations (AMP at
different doses, then L-Arginine at different doses,
then the combination AMP–L-Arginine) to the
strips under precontracted conditions. The ﬁnal
bath concentrations were between 10−4 M and
10−3 M. Nitric oxide (NO) synthase inhibitor
N-nitro-L-arginine (L-NNA) at the dose of
5.10−4 M was also administered to the strips before
treatment with AMP.
Statistical Analysis
Contraction percentages were compared between
groups by a variance analysis in repeated measure-
ments. A value of P < 0.05 was considered signiﬁ-
cant in all tests. All results are expressed as
mean ± standard error of the mean.
Results
The maximal relaxing effect after addition of
active substances was measured at each stage (for
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each concentration) and was reached in appro-
ximately 1 minute as shown in Figure 1. The
number of single strips for each experiment was
n = 12.
AMP-Induced Relaxation
Muscles were precontracted by PE 20 μM. Expo-
sure of this preparation to AMP led to a signiﬁcant
(P < 0.001) relaxation level that reached 11.7% at
5.10−4 M and 25% at 10−3 M (see Figure 2).
When L-NNA was used before AMP, the relax-
ation produced by AMP at 5.10−4 M and at 10−3 M
was strongly inhibited, i.e., limited to 6.7% and
6.9%, respectively. The relaxing effect was signiﬁ-
cantly different with and without L-NNA, espe-
cially at AMP 10−3 M (P = 0.009).
A
B
Figure 1 Dose-response curve over time for L-Arginine (A) and adenosine monophosphate (B). AMP = adenosine
monophosphate; Larg = L-Arginine; PE = phenylephrine; WO = wash-out
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Figure 2 AMP-induced relaxation on corpus cavernosum
precontracted with phenylephrine (20 μM). Vertical bars
indicate SEM, (n = 12). AMP = adenosine monophosphate;
SEM = standard error of the mean
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L-Arginine-Induced Relaxation
When L-Arginine was used to induce relaxation
after a precontraction to PE, the relaxation was
15.6% at 5.10−4 M in a concentration-dependent
way (P < 0.001). The results are presented in
Figure 3.
AMP/L-Arginine-Induced Relaxation
Precontraction with PE was induced before a
concentration-dependent curve to AMP (5.10–4
and 10–3 M) followed by different L-Arginine
concentrations of (10–4, 2.10–4, and 5.10–4 M).
The results (see Figure 4) show that under these
experimental conditions, AMP induced a signiﬁ-
cant (P < 0.0001) relaxation (16.5% at 5.10–4 M
and 37% at 10–3 M). When L-Arginine 5.10–4 M
was added, the AMP-induced relaxation was sig-
niﬁcantly enhanced; at AMP 5.10–4 M, a 41%
relaxation was reached (vs. 16.5% without
L-Arginine) and at 10–3 M, a 58% relaxation was
reached (vs. 37% without L-Arginine).
A synergistic effect was demonstrated with these
two compounds as the ﬁnal result was superior to
the addition of the two effects obtained separately
(15.6% for L-Arginine alone). To conﬁrm this
result, the response induced by L-Arginine alone
was substracted from that induced by L-Arginine
with AMP and the result compared with AMP
without L-Arginine. Using paired tests and com-
paring AMP without L-Arginine to AMP with
L-Arginine, a signiﬁcant difference was found
between the two, whatever the AMP dose used
(P = 0.0012 and P = 0.0345, respectively). These
differences not only demonstrate the potentiating
effect induced on the rabbit CC response when
L-Arginine was combined to AMP but also the
existence of a clear synergistic effect. In fact, the
sole addition of the relaxing effect induced by
the two substances used separately was not sufﬁ-
cient to explain the increase of the AMP response
in the presence of L-Arginine.
Discussion
The multifaceted nature of FSD is clearly distinct
from that of the male [10] and generally regarded
as being much more complex [11,12], involving a
multitude of different factors such as the status of
sex steroid hormones (testosterone, estrogens),
critical in the maintenance of tissue structure
and function, several central and peripheral
reﬂex mechanisms (pelvic, hypogastric, pudendal
nerves, lumbosacral spinal cord, thalamus, hypo-
thalamus and at least ﬁve brain nuclei with their
related neurotransmitters: norepinephrine, sero-
tonin, dopamine, histamine, opioids and gamma-
aminobutyric acid), various speciﬁc vasculogenic
mediators (mainly vasoactive intestinal peptide,
neuropeptide Y and NO) and moreover, psycho-
logical aspects. Amid this wide variety of key
factors, the clitoris engorgement with blood due
to sexual excitement plays a crucial functional
role during intercourse in provoking orgasm
[9,13] or at least pleasure and is essential to the
maintenance of a normal sexual condition in
female mammals.
No immunohistochemical or morphological
differences have been reported between the penis
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Figure 3 L-Arginine-induced relaxation on corpus
cavernosum precontracted with phenylephrine. Vertical
bars indicate SEM, (n = 12). SEM = standard error of the
mean
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Figure 4 AMP (5.10−4 and 10−3 M)/L-Arginine (5.10−4 M)
association-induced relaxation on corpus cavernosum
precontracted with phenylephrine. Vertical bars indicate
SEM, (n = 12). AMP = adenosine monophosphate;
SEM = standard error of the mean
4 Stücker et al.
Sex Med 2014;2:1–7 © 2014 The Authors. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
and the clitoris in humans [3,8] with the exception
of the subalbugineal layer [13,14]. In men, this
area contains a rich venous plexus that is crushed
during erection resulting in penile rigidity. The
absence of this speciﬁc area in the clitoris limits the
effects of the CC blood ﬁlling, which only leads to
a tumescence. Therefore, safe drug helpers can be
used, not only to induce this tumescence when
required but also to ensure its maintenance during
intercourse, which even makes much more sense
in women with sexual arousal disorders than in
men.
The female New Zealand rabbit is considered a
reliable animal model to study clitoral engorge-
ment and has been shown to characterize the
mammal female sexual arousal response [7,15].
The existence of a clitoral adrenergic tone and the
implication of the NO pathway, as a key mediating
factor in clitoris smooth muscle relaxation, have
also been well established [9,15–17]. In many
respects, the overall vascular mechanisms that
engorge the female erectile tissue are close to
those already identiﬁed in the male erectile tissue.
As a consequence, similar vasoactive medications
could theoretically be used for both sexes.
However, to date, subsequent experimental data
have not been as conclusive as originally antici-
pated by the theory.
Several medications have been studied for their
vasoactive effects on the female genitalia from
which only two have emerged, estrogens [18] and
phosphodiesterase type 5 inhibitors (iPDE5).
Estrogens, whether or not combined with
progestin therapy, can be used orally or topically.
However, because the decision to use hormone
therapy (HT) during menopause is made by each
woman and her physician after weighing the ben-
eﬁts and possible risks of breast, endometrial,
ovarian cancers, including other types of cancer
(the lung for example), and not least the risk of
cardiovascular diseases [19], it is clear that in many
cases, FSAD alone does not justify the use of HT.
In contrast to their use in men, iPED5 has failed to
demonstrate consistent efﬁcacy in women [20,21]
except in those individuals with depression treated
by selective serotonin reuptake inhibitors [22]. On
the whole, iPDE5 has produced mixed preclinical
results and equivocal human clinical results that
did not encourage the Federal Drug Administra-
tion to approve this class of products for FSAD.
The most interesting data to date have been
provided by a topically applied formulation of
0.4% alprostadil [23]. However, this prostaglandin
E1 cream has not yet been approved; moreover,
some women or their partners dislike the use of
topical treatments for intercourse. Thus, there is a
need for alternatives and possibly oral treatments.
To our knowledge, there are no previously
reported studies that have assessed the potential
effect on the rabbit clitoral tissue of AMP alone or
a combination of AMP with an NO donor. This
includes ﬁndings based on our previous studies in
the rabbit and human male [24].
In the present work, we demonstrated that (i)
AMP signiﬁcantly relaxes the CC of the female
New Zealand White rabbit, however, compara-
tively not as much as it relaxed the male New
Zealand White rabbit CC at identical concentra-
tions (25% in female vs. 42% in male [2]); (ii)
L-Arginine at 10–4 M was twice as potent on the
female than on the male CC strips (16% vs. 8%);
and (iii) the combination of AMP with L-Arginine
potentiated each of other substance and induced a
strong synergistic effect on the female CC strips
(41% at AMP 5.10–4 M and 58% at AMP
10–3 M), which is approximately within the same
range as the one observed on male rabbit CC strips
(43% at AMP 5.10–4 M and 61% at AMP
10–3 M).
These results suggest that many similarities
exist between both sexes in response to NO donors
and AMP or their combination when these sub-
stances are tested on rabbit erectile tissue. It also
indicates that very close biochemical mechanisms,
although not to the same degree, are probably
involved in the engorgement of the penis and the
clitoris of the New Zealand White rabbit.
However, there are also some differences: as
opposed to what was observed in the male rabbit
CC strip experiment, the effect of AMP on the
rabbit clitoral tissue was linked to the NO pathway
because L-NNA strongly inhibited the relaxation
induced by AMP.
AMP is considered as an intermediary substance
formed during the body’s process of creating
energy in the form of adenosine triphosphate
(ATP). However, it does not activate P2 receptors
[25]. Under physiological conditions, AMP
behaves as a natural “adenosine precursor” that is
ultimately converted into adenosine by ecto-5′-
nucleotidases on the extracellular surface of all
cells (due to this enzyme which has a very high
afﬁnity for AMP). Therefore, it is primarily seen as
an agonist of adenosine/P1 receptors. Until the
year 2012, there was no known speciﬁc AMP
receptor in mammals. GPR80/GPR99, a P2Y
receptor originally classiﬁed as an adenosine and
AMP receptor [26], has since been discounted
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[27,28]. A recent work using a novel cell-based
assay to visualize adenosine receptor activation in
real time associated with full inhibition of ecto-5′-
nucleotidases activity could determine that AMP is
in fact a direct A1 receptor agonist [29]. However,
under normal conditions, ecto-5′-nucleotidases
are not inhibited to the extent that AMP mainly
acts through adenosine and not as a direct activa-
tor of P1 receptors.
Curiously enough, while P1 adenosine recep-
tors, in particular the A2a and A2b subtypes, are
widely present in the male CC of human, rabbit,
and many other species, to our knowledge and to
date, no P1 adenosine receptors have been found
in the clitoral tissue of mammals. In contrast, the
presence of P2Y receptors that recognize ATP,
adenosine diphosphate, uridine triphosphate, and
uridine diphosphate but not AMP, has been iden-
tiﬁed in rabbits and humans [12,30] localized to
endocervical and cervical glands, epithelium, and
stratiﬁed squamous epithelium of the vagina with a
function of lubriﬁcation (stimulation of mucin
secretion and chloride efﬂux).
The mechanism by which AMP induces female
CC relaxation and interferes with the NO pathway
is still unclear. Results in the female rabbit are
comparable with those observed in the male rabbit
with a higher response to AMP in the latter case
and a more important L-Arginine-induced stimu-
lation of the NO pathway in the former case. AMP
is known to mainly act in mammals through the
stimulation of vascular adenosine receptors.
Although adenosine A2a receptors are found in the
endothelia and vascular smooth muscle cells of the
rabbit [31], to date, they have not been described
in the clitoral CC of this animal model. In fact, it
appears that no research has ever been conducted
to explore this speciﬁc point. Our results
prompted us to do so and to go deeper into the
action mechanism.
As regards the complexity of the phenomenon
involved in female CC relaxation, effective
vasoactive agent combinations such as those
described in our study should be considered as an
interesting approach for the treatment of FSD. In
the case of AMP and its combination to
L-Arginine, further basic research and preclinical
testing are warranted.
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